Sign in
Taking people in United StatesPhase 2

Tests a patient's own platelet-rich fibrin for chronic diabetic foot ulcers

Tests a patient's own platelet-rich fibrin on diabetic foot ulcers in adults.

Key facts

Who runs it
Estar Medical dba Medical Technologies, LTD
Where
Corpus Christi, United StatesSee the 2 sites
Trial code
Registry title
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
15 Apr 2025
Planned end
15 Aug 2026
Type of study
Interventional
Treatments tested
  • Platelet Rich Plasma
Record updated
12 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 80 with type 1 or type 2 diabetes and a non-infected, mild to moderate diabetic foot ulcer that has not been healing.

Age
18 to 80 years
Sex
Men and women can join.
Disease stage
A non-infected diabetic foot ulcer below the ankle, Grade 2 as listed (Wagner Grade 1 or 2 in the title), 1.0 to 12.0 cm2 in size and present for at least 30 days. Depth of 5 mm or less, with enough blood flow to the limb.
Earlier treatment
The ulcer must have had standard care for 2 weeks with 20% or less wound closure. No electrostimulation, hyperbaric treatment, growth factors or cell or tissue-derived therapy for wounds in the 30 days before entry. No radiation or chemotherapy in the previous 3 months.
Biomarker or test result
HbA1C of 12% (108 mmol/mol) or less. Platelet count of at least 105,000 and below 450,000. Hemoglobin of at least 10 g/dL and hematocrit of at least 27%. Adequate blood flow in the limb, for example ABI 0.65 to 1.2 or toe pressure of at least 30 mmHg.

Main reasons for not taking part

  • Infection, sepsis or bone infection (osteomyelitis) at the wound or limb
  • Kidney failure needing dialysis
  • Blood clotting problems, platelet disorders or blood disease such as sickle cell anemia or leukemia
  • Another clinical trial with a device or investigational drug within 30 days
  • Systemic corticosteroids or immune-suppressing treatment within 30 days

The registry criteria, word for word

Show all 47 criteriaShow less

Who can take part

  • Male or female ≥ 18 years of age
  • Type 1 or Type 2 Diabetes
  • Grade 2, DFU, non-infected, below the ankle,1.0-12.0 cm2, present ≥ 30 day
  • Ulcer Size 1.0 cm2 to 12.0 cm2
  • Wound location will be distal to the malleolus, excluding between the toes, with no exposed capsule, tendon, or bone, and no tunneling, undermining, or sinus tracts, a depth of ≤ 5mm
  • If more than one non-healing wound is present, the selected ulcer will be the largest and ≥ 1 cm2 in size
  • At least 2.0 cm between the index wound and other wounds
  • Study ulcer has been present for at least 30 days and has undergone the 14-day
  • Adequate vascular perfusion of the affected limb, as defined by at least one of the following: Ankle-Brachial Index (ABI) ≥ 0.65 and ≤ 1.2, Toe Pressure (TP) ≥ 30 mmHg, Transcutaneous partial pressure of oxygen (TcPO2) ≥ 30 mmHg, or skin perfusion pressure (SPP) ≥ 30 mmHg
  • WIFI SCORE- wound grade 1, ischemia grade 0-1, and infection grade 0)
  • Screening Period of the standard of care with 20% or less wound closure
  • No Clinical Signs of Infection at the wound site or the affected limb
  • Post-debridement without signs of necrotic tissue
  • Normal Platelet count ≥ 105,000 and <450, 000 (according to CBC)
  • Hemoglobin (Hgb) ≥10 g/dL and Hematocrit (HCT) ≥ 27% (according to CBC)
  • Controlled glucose level HbA1C ≤ 12%, with active treatment being conducted to reduce the value to by a primary provider or endocrinologist
  • No Chronic Renal Failure (CRF); Estimated glomerular filtration rate (eGFR) ≥ 15
  • PT/PTT - INR between 2.0-3.0 (with blood thinners)
  • Nutritional Status with no severe protein deficiency, Pre-albumen >15 mg/dL
  • Demonstrated adequate offloading using DH Walker boot with Plastazote Insole (OR equivalent off-loading device)
  • If a female of childbearing potential, must have a negative serum or urine pregnancy test at screening and use contraception or abstinence during trial
  • Male subjects agree to use contraception or abstinence during the trial
  • The subject has provided written informed consent before any screening procedures and agrees to comply with study procedures and requirements

Who cannot take part

  • Participation in another clinical trial involving a device or a systematically administered investigational study drug or treatment within 30 days
  • Alcohol or substance abuse (other than tobacco) within 2 months before enrollment
  • Participation in another clinical trial involving a device or a systematically administered investigational study drug or treatment within 30 days of initiating the trial
  • Received electrostimulation, hyperbaric treatments, growth factors, or any cell or tissue-derived therapy for any wounds 30 days before entry into the study
  • Systemic corticosteroids, (except for subjects receiving inhaled corticosteroid treatments for asthma or COPD) 30 days before entry into the study
  • Received within 30 days before the study or scheduled to receive medications or treatments known to interfere with or affect the rate or quality of wound closure (e.g., systemic steroids, immunosuppressive therapy, autoimmune disease therapy within the past 12 months, dialysis, radiation therapy to the treatment area, vascular surgery, angioplasty, or thrombolysis
  • Received radiation therapy or chemotherapy within the previous 3 months
  • Soft tissue infection at the designated ulcer or the same extremity within 2 weeks of the time of screening
  • CKD Level G5: Chronic Renal Failure (CRF) sufficient to require dialysis
  • Blood-borne or communicable diseases that would likely prevent full participation in the trial (e.g., HIV, AIDs, COVID, TB)
  • Anemia Hgb ≤ 10 g/dL and HCT ≤ 27%
  • History of problems with coagulation, abnormal thrombocytes (platelets), or receiving heparin intravenously; subjects taking coumadin, aspirin, clopidogrel, or other oral anti-coagulants are not excluded
  • Life expectancy is less than 12 months
  • Ulcers of other than diabetic foot pathophysiology
  • Documented sepsis, proven with blood cultures, within 2 weeks of the trial or during the Screening Phase
  • Osteomyelitis at the designated wound site; using ESR ≥ and /or CRP ≥ 7.9 mg/d as a screen
  • Religious constraints to using blood products, including autologous blood
  • The subject has severe lymphedema (Stage 3) where the individual cannot lift the extremity on their own secondary to the amount of edema and fluid weight
  • The subject is undergoing hemodialysis
  • Subjects who are cognitively impaired, unable to understand the informed consent, or have a health care proxy
  • Subjects with sickle cell anemia, thrombocytopenia, leukemia, or blood dyscrasia
  • Anemia where weekly blood draws of 12 or 23 per week may not be tolerated
  • Subjects with known sensitivity to blood components such as those in the PRF kit
  • The subject has inadequate venous access for repeated blood draws required for the PRP preparation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • WoundCentrics Wound Care & Hyperbarics -Corpus Christi - ShorelineCorpus Christi, United StatesContact: Tarek Ibraham, MBATaking people
  • Woundcentrics Wound Care Center At Corpus Christi SouthCorpus Christi, United StatesContact: Tarek Ibrahim, MBATaking people

About the trial

What the trial wants to find out

The goal of this investigational study is to evaluate the safety and clinical performance of Tropocells Autologous Platelet-rich Fibrin (PRF) for wound care for both males and females, ages 18-80 years old, with Grade 1 and 2, mild to moderate, neuroischemic diabetic chronic foot ulcers in subjects with Type 1 and Type 2 Diabetes Mellitus. The main question[s] it aims to answer [is/are]:

Read full original descriptionShow less

Measure 1: Wound Closure with Tropocells Autologous PRF System for DFU Measure 2: Safety of Tropocells Autologous PRF System for DFU Researchers will enroll to acquire approximately 30 evaluable subjects with no comparison group.

Run-In Phase (2 weeks): participants with chronic diabetic foot wounds will undergo a 2-week run in phase presenting to the clinic for weekly visits, for standard of care.

Active Treatment Phase (12 weeks): participants that do not show a reduction of at least 20% may be qualified to advance to the active treatment phase where wounds will be evaluated and treated weekly in the research clinic to receive standard of care with Tropocells Autologous PRF System.

Follow-up Phase (1 month and 3 months): participants with wounds that losed during the Active Treatment Phase ( 100% wound closure with two weekly assessments demonstrating persistent closure) will be advanced to the follow-up phase to show if the wound remains closed at 1 month and 3 months.

The group in the trial

  • T1DM,T2DM participants with non-infected, neuroischemic, chronic foot ulcersTreatment being tested

    During Screen-the participant will be treated with standard of care (SOC) for 2 weeks, including education, nutritional supplement, weekly wound assessments and care with off-loading. After the two weekly visits, subjects who meet the inclusion/exclusion criterion, show adequate perfusion and area reduction less than 20%, and comply with the standard of care will be enrolled in the Active Treatment Phase. During the Active Treatment Phase, subjects will be treated weekly with TropoCells® Autologous Platelet-rich Fibrin (PRF) for twelve (12) weeks and continued SOC. Wound area will be documented with measures and photographs before and after cleansing and debridement (as needed). Clean wounds treated topically with active therapy will be covered with a non-adherent layered absorbent foam dressing with an external protective third layer. Mild compression will be applied with continued off-loading at least 2 week after closure. Follow-up evaluation after closure at 1 and 3 months.

    Treatment: Platelet Rich Plasma

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
EVALUATION OF THE SAFETY AND THE CLINICAL PERFORMANCE IN TREATMENT OF CHRONIC DIABETIC FOOT ULCER, WITH THE TROPOCELLS®, BASED AUTOLOGOUS PLATELET RICH FIBRIN (Tropocells(R) Autologous PRF Systems)
Plain-language title
Tests a patient's own platelet-rich fibrin for chronic diabetic foot ulcersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06810726, who can take part
Record updated
12 June 2025